This content is PDF only. Please click on the PDF icon to access.
Abstract
Topical application of idoxuridine (IDU) is presently a standard treatment for epithelial herpes simplex keratitis in man. While IDU therapy is usually satisfactory, clinically resistant keratitis has been encountered. In most instances, the actual basis of these IDU treatment failures is never determined. On occasion, viral isolates from such cases have proved to be biochemically resistant to IDU.1 An important attribute for any new antiherpes drug would be its ability to successfully manage cases in which IDU failed clinically, including those in which the infecting virus was biochemically resistant to IDU.